Results 181 to 190 of about 34,140,631 (244)
Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis. [PDF]
Ghosal S, Ghosal A.
europepmc +1 more source
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney +14 more
wiley +1 more source
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo +4 more
wiley +1 more source
Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
Sanjay Kalra +2 more
doaj +1 more source
Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist. [PDF]
Kim AR +6 more
europepmc +1 more source
This large multicentre retrospective cohort study in Australia revealed that despite being younger and having greater preoperative comorbidity and higher HbA1c levels, Aboriginal and Torres Strait Islander adults with diabetes mellitus demonstrate higher rates of perioperative hypoglycaemia, but otherwise comparable markers of glycaemic variability and
Katerina Flabouris +5 more
wiley +1 more source
The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. [PDF]
Israel A +8 more
europepmc +1 more source
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando +3 more
wiley +1 more source
Body Mass Index-Dependent Effect of Glucagon-Like Peptide 1 Receptor Agonist Therapy on Bowel Preparation Quality. [PDF]
Vikash FNU +4 more
europepmc +1 more source

